Fate of PNH clones after extended follow-up
| . | 0 mo . | 3 mo . | 6 mo . | 9 mo . | 1 y . | 2 y . | 3 y . | 4 y . |
|---|---|---|---|---|---|---|---|---|
| A1 | 15.3 | 8.8 | 21 | 32 | 37 | 43 | 69 | NA |
| A2 | 7.6 | 4.5 | 5.6 | 13 | 9.7 | 5.3 | 3.4 | NA |
| A3 | 7.6 | 1.5 | 2.7 | ND | 2.4 | 2.4 | NA | NA |
| A4 | 6.4 | 1.6 | ND | ND | 3.7 | 15 | NA | NA |
| A5 | 8.9 | 15.8 | 11.6 | 10 | 10 | 8 | NA | NA |
| C1 | 1.2* | NA | NA | NA | NA | NA | NA | NA |
| C2 | 83 | 36 | 65 | 56 | 62 | 27 | 29 | 60 |
| C3 | 2.3 | ND | 0.7 | 0.7 | 0.5 | 0.3 | NA | NA |
| C4 | 23* | NA | NA | NA | NA | NA | NA | NA |
| C5† | ND | 80.8* | NA | NA | NA | NA | NA | NA |
| . | 0 mo . | 3 mo . | 6 mo . | 9 mo . | 1 y . | 2 y . | 3 y . | 4 y . |
|---|---|---|---|---|---|---|---|---|
| A1 | 15.3 | 8.8 | 21 | 32 | 37 | 43 | 69 | NA |
| A2 | 7.6 | 4.5 | 5.6 | 13 | 9.7 | 5.3 | 3.4 | NA |
| A3 | 7.6 | 1.5 | 2.7 | ND | 2.4 | 2.4 | NA | NA |
| A4 | 6.4 | 1.6 | ND | ND | 3.7 | 15 | NA | NA |
| A5 | 8.9 | 15.8 | 11.6 | 10 | 10 | 8 | NA | NA |
| C1 | 1.2* | NA | NA | NA | NA | NA | NA | NA |
| C2 | 83 | 36 | 65 | 56 | 62 | 27 | 29 | 60 |
| C3 | 2.3 | ND | 0.7 | 0.7 | 0.5 | 0.3 | NA | NA |
| C4 | 23* | NA | NA | NA | NA | NA | NA | NA |
| C5† | ND | 80.8* | NA | NA | NA | NA | NA | NA |
The percentage of GPI-anchored protein-deficient granulocytes is shown over time in patients randomly assigned to ATG (A1-5) or Cy (C1-4) in whom at least one value was above the threshold of 1%. Two patients (A1 and C2) have developed evidence of intravascular hemolysis.
ND indicates not done; NA, follow-up not reached.
Patient died prior to subsequent follow-up.
Patient treated by compassionate exemption for primary PNH (values at 1 mo, 92%; at 2 mo, 55.4%).